Semaglutide
Also referred to as: GLP-1 receptor agonist, NN9535
A peptide that mimics a natural gut hormone (GLP-1) involved in blood sugar and appetite. The most widely studied and best-known peptide in the weight and metabolic space.
In plain terms: Semaglutide copies a natural gut hormone your body makes after eating — one that helps control blood sugar and makes you feel full. It has been studied heavily in people for blood sugar and weight and fat loss, and is approved as a medicine in many places for specific uses.
- Name
- Semaglutide
- Aliases
- GLP-1 receptor agonist, NN9535
- Classification
- GLP-1 receptor agonist (peptide)
- Areas studied
- Blood-sugar signals, Appetite, Weight & fat loss
What it is
Semaglutide is a lab-made peptide that closely mimics GLP-1, a hormone your gut releases after you eat. GLP-1 helps the body manage blood sugar and signals the brain that you are full. Semaglutide is built to last far longer in the body than the natural hormone, so it keeps that signal going.
It has one of the largest human research records of any peptide and is approved as a medicine in many countries for specific uses.
Mechanism
Semaglutide plugs into the GLP-1 docking point (receptor) on cells. (A receptor is the dock a hormone plugs into to send its signal.) Switching on this signal helps the body release insulin when blood sugar is high, slows how fast the stomach empties, and reduces appetite.
Researchers study how these combined effects influence blood sugar and weight and fat loss.
Areas studied & investigated
The categories below summarize where Semaglutide appears in the research literature. They describe what the compound is studied for and investigated in — not approved uses, and not guidance for any kind of use.
Blood-sugar control
Studied for how it helps the body manage blood sugar through the GLP-1 signal.
Appetite
Looked at for how it reduces hunger by signaling fullness to the brain.
Weight & fat loss
Studied extensively in clinical trials in connection with body weight and fat loss.
Heart & metabolic health
Studied in large trials for effects on heart-related outcomes in specific populations.
Research history
Semaglutide grew out of decades of research into GLP-1 hormones for blood sugar. It moved through large registered clinical trials in the 2010s and was later studied specifically for weight, with results in major medical journals.
State of the literature
Semaglutide has a very large body of peer-reviewed human research and is approved in many places for specific uses. Use outside those approved uses, or with a research-use-only product, is not established.
What to keep in mind
Semaglutide is approved and heavily studied — but that data comes from a regulated medicine used under medical supervision at specific doses. A research-use-only product bought online is not the same thing, even if the molecule is the same name. The safety record you read about does not transfer to unsupervised use. Keep the approved-medicine world and the research-product world separate.
Research tools
Evaluating a Semaglutide batch for laboratory research? These free, research-use-only calculators help you work the numbers and read the paperwork: the reconstitution calculator solves vial concentration and draw volume, and the COA reader walks a certificate line by line. For how much and how often Semaglutide is commonly used, see the dosing guides.
Batch-tested with published COAs
Semaglutide on the store
Midwest Compounds sells Semaglutide. Every batch is tested by an independent lab and the certificate is published on the COA page as soon as it is issued. This page is educational; purchasing happens on the store.
Citations
The summary above is drawn from published, peer-reviewed sources. Links open the abstract on PubMed, or the free full text on PubMed Central (PMC) where marked.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021. Abstract
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016. Abstract